We are live on
!
Find out more
IMUC
ImmunoCellular Therapeutics, Ltd.
IMUC
IMUC
Delisted
IMUC was delisted on the 16th of October, 2018.
39 hedge funds and large institutions have $3.56M invested in ImmunoCellular Therapeutics, Ltd. in 2014 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 8 increasing their positions, 11 reducing their positions, and 5 closing their positions.
New
Increased
Maintained
Reduced
Closed
1,675% more call options, than puts
Call options by funds: $71K | Put options by funds: $4K
7% less funds holding
Funds holding: 42 → 39 (-3)
21% less capital invested
Capital invested by funds: $4.51M → $3.56M (-$948K)
27% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 11
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Holders
39
Holders Change
-3
Holders Change %
-7.14%
% of All Funds
1.13%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
8
Reduced
11
Closed
5
Calls
$71K
Puts
$4K
Net Calls
+$67K
Net Calls Change
+$85K
Top Buyers
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$213K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$48.4K |
| 3 |
U
UBS
Zurich,
Switzerland
|
+$44.1K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$38.1K |
| 5 |
D.E. Shaw & Co
New York
|
+$13.4K |
Top Sellers
| 1 |
Morgan Stanley
New York
|
-$119K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$99.5K |
| 3 |
VKH
Virtu KCG Holdings
New York
|
-$58.6K |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$42K |
| 5 |
GC
Guggenheim Capital
Chicago,
Illinois
|
-$25K |
